PD-(L)1
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study (NCT07004335) | Hebei Medical University Fourth Hospital | 2025-07-01 |
Track PD-(L)1 automatically
Every clearance here is in the API, with alerts when new ones post.